LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Invitation to the presentation of Calliditas Therapeutics' interim report January - March 2024

May 16, 2024 | Last Trade: US$40.00 0.00 0.00

STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas's interim report for the first quarter, January - March 2024 will be published in Swedish and English on Thursday 23 May 2024 at 07.00 a.m. CET.

A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén.

The presentation will be given in English.

Link to the webcastCalliditas Therapeutics Q1 Report 2024 (financialhearings.com)

To participate via conference call please register via this link: https://conference.financialhearings.com/teleconference/?id=50047214

After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.

For further information, please contact:

Åsa Hillsten, Head of IR & Sustainability, Calliditas

Tel. +46 76 403 35 43, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

The information was sent for publication, through the agency of the contact person set out above, on 16 May, 2024, at 8:30 a.m. CET.

 

Viking Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB